Document:

EX-10.10

 Exhibit 10.10 

CONSULTING AND NON-COMPETITION AGREEMENT 

THIS CONSULTING AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into as of this 21st day of May, 2010 (the
“Effective Date”), by and among EndoStim, Inc., a Delaware corporation (the “Company”), and Virender K. Sharma, M.D. (“Consultant”). 

WITNESSETH: 
 WHEREAS, Consultant
desires to provide services to the Company as a consultant as set forth below; and 
 WHEREAS, the Company desires to receive the benefit of
the services of Consultant and Consultant is willing to render such services on the terms and conditions hereinafter set forth. 
 NOW,
THEREFORE, in consideration of the mutual promises hereinafter set forth, it is hereby agreed as follows: 
 1. Appointment. Subject
to the terms and conditions of this Agreement, the Company hereby engages Consultant, and Consultant hereby agrees to perform for the Company the services described in Section 3 of this Agreement. 

2. Term. The term of Consultant’s appointment under this Agreement shall commence on the Effective Date. Consultant reserves the
right to terminate Consultant’s relationship with the Company at any time, and the Company reserves its right to terminate Consultant at any time, with or without “Cause” (as defined in Section 7), for any reason or for no
reason. The period between the Effective Date and termination of the consulting arrangement shall be known as the “Consulting Period.” 

3. Duties. 
 (a)
Consultant shall serve as the Company’s Chief Medical Officer. Consultant shall report to the Chief Executive Officer and the Board of Directors (the “Board”), shall disclose to the Company any inventions, know-how and ideas related
to the “Field” (as such term is defined in Section 6(e)), and shall provide medical expertise to the Company. Consultant shall be the liaison between the Company and medical providers. 

(b) The Company recognizes that Consultant has and will have other responsibilities and obligations to other organizations on a full-time
basis. Notwithstanding this fact, Consultant will devote such time and energy to his position with the Company as reasonably necessary to fulfill Consultant’s obligations to the Company, provided that Consultant shall not be required to
provide services on more than a part-time basis unless he agrees otherwise. 

 4. Consideration. 

(a) Stock Issuance. On the Effective Date, the Company will issue Consultant (or a designee thereof) 50,000 shares of the
Company’s common stock, $0.001 par value, which shall be subject to the terms and conditions of (i) that certain Stockholders Agreement of the Company, by and among the Company and the other holders of the Company’s common stock as in
effect on the Effective Date, and (ii) a Restricted Stock Agreement between the Company and Consultant in the form attached as Exhibit A to this Agreement. 

(b) Cash Payments. Except for the reimbursement of reasonable expenses incurred in connection with the performance of Consultant’s
duties to the Company, Consultant will not be eligible to receive any cash compensation from the Company for his services under this Agreement until the Company has completed a sale of its Series B Preferred Stock or similar round of financing,
after which any cash compensation will be as may mutually be agreed upon by the Company and Consultant. 
 (c) Withholding and Other
Taxes. Any and all compensation paid to Consultant shall be subject to customary withholding taxes and other taxes as required with respect thereto. 

5. Confidential Information. 

(a) Consultant, during the Consulting Period and thereafter, agrees to keep secret and confidential, and not to use or disclose (directly or
indirectly) to any third parties, any of the Company’s Confidential Information (as defined below). 
 (b) Consultant acknowledges and
confirms that certain data and other information (whether in human or machine readable form and whether or not previously owned by Consultant or its affiliates) that comes into Consultant’s possession or knowledge (whether before, on, or after
the Effective Date) and which was developed for or obtained from the Company, or obtained by Consultant for or on behalf of the Company, whether identified as confidential or not (collectively, the “Confidential Information”) is the
secret, confidential property of the Company. Notwithstanding the foregoing, Confidential Information of the Company is deemed to include, but is not limited to: 

(i) lists or other identification of customers or licensees or prospective customers or licensees of the Company (and key individuals employed
or engaged by such parties); 
 (ii) lists or other identification of sources or prospective sources of the Company’s products or
technology or components thereof (and key individuals employed or engaged by such parties); 
 (iii) financial, sales and marketing data
relating to the Company or to the industry or other areas pertaining to the Company’s activities and contemplated activities (including, without limitation, manufacturing, transportation, distribution and sales costs and non-public pricing
information); 

  
 2 

 (iv) the Company’s relations with its customers, prospective customers, suppliers and
prospective suppliers, licensees and prospective licensees and the products or services rendered or licensed to such customers or licensees (or proposed to be rendered to prospective customers or licensees); 

(v) the Company’s relations with its employees and consultants (including, without limitation, salaries, job classifications and skill
levels); 
 (vi) information relating to the Company’s intellectual property and the development thereof; and 

(vii) any other information known by Consultant to be confidential, secret and/or proprietary (including without limitation, information
provided by customers, licensors, licensees or suppliers of the Company). 
 (c) Consultant hereby acknowledges that all Confidential
Information is considered confidential by, and is exclusively proprietary to and a valuable trade secret of, the Company and derives independent economic value, actual or potential, to the Company from not being generally known to, and not being
readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use. Consultant will not copy, reproduce or otherwise duplicate, record, abstract, summarize or otherwise use, any papers, records, reports,
studies, computer printouts, equipment, tools or other property owned by the Company except as expressly permitted by the Company in writing. 

(d) Notwithstanding the foregoing, “Confidential Information” shall not include any of the foregoing or other data or information
which: (i) has been made available to a third party by the Company or by a third party without an obligation of confidentiality; (ii) is or becomes available in the public domain, other than by Consultant in violation of this Agreement;
(iii) was approved by the Company, in writing, for release or further disclosure; (iv) was disclosed to or learned by Consultant by or from a third party, either before or after disclosure by the Company and without breach of a known
obligation of confidence by the third party; or (v) that relates to any of Consultant’s preexisting Work Product (as defined in Section 6(e)), but only with respect to such Work Product that is specified on Exhibit B
attached to this Agreement. 
 6. Inventions, Etc. 

(a) Ownership. Consultant hereby assigns to the Company all of Consultant’s rights, title, and interest (including but not limited
to all patent, trademark, copyright and trade secret rights) in and to all Work Product related to the Field (as such terms are defined in Section 6(e)) prepared by Consultant, made or conceived in whole or in part by Consultant during
Consultant’s engagement with the Company or within six (6) months thereafter or that relate directly to or involve the use of Confidential Information, and all rights to sue or recover for past infringement thereof. Consultant further
acknowledges and agrees that all copyrightable Work Product related to the Field and prepared by Consultant during Consultant’s engagement with the Company are “works made for hire” and, consequently, that the Company owns all
copyrights thereto. 

  
 3 

 (b) Disclosure. Consultant will promptly disclose to the Company all Work Product related
to the Field developed by Consultant during Consultant’s engagement with the Company or within six (6) months thereafter, including all inventions, discoveries, improvements and trade secrets related to the Field which are or have been
made or conceived by Consultant, individually or jointly with others, during his engagement by the Company and within six (6) months thereafter, or during Consultant’s prior period(s) of engagement with the Company, if any, and which
relate to, result from, or arise in any way out of any work done for the Company or any information or assistance provided by the Company. All such Work Product related to the Field is and shall forthwith become the property of the Company, whether
or not patentable or copyrightable. During the Consulting Period and thereafter, Consultant will execute promptly upon request any documents or instruments at any time deemed necessary or proper by the Company in order to formally convey and
transfer to the Company title to such Work Product related to the Field, or to confirm the Company’s title therein, or in order to enable the Company to obtain and enforce United States and foreign letters patent, trademarks and copyrights
thereon. Consultant will perform his obligations under this Section 6 without further compensation, except for reimbursement of reasonable out-of-pocket expenses incurred at the request of the Company. If Consultant refuses, following
ten (10) days’ prior written notice from the Company, or is unable due to disability or incapacity, to execute any such documents relating to Work Product related to the Field, Consultant hereby appoints each officer and director of the
Company to be his Attorney-in-Fact to so execute such documents on behalf of Consultant. This shall be a durable Power of Attorney, the authority of which shall not terminate if Consultant becomes disabled or incapacitated. If Consultant is unable
due to death to execute any such documents relating to Work Product, Consultant covenants and agrees that his heirs, successors, estate and personal representative are hereby authorized and directed to execute such documents on behalf of Consultant,
and upon the failure of such heirs, successors, estate and personal representative to execute such documents, Consultant does hereby authorize each officer and director of the Company to so execute such documents on behalf of Consultant’s
heirs, successors, estate and personal representative. Notwithstanding anything contained in any other durable Power of Attorney, this agency is coupled with an interest and is therefore irrevocable without the prior written consent of the Company.

 (c) Preexisting Work Product Not Assigned. Consultant has specified on Exhibit B attached to this Agreement all preexisting
Work Product that was created by Consultant prior to Consultant’s engagement by the Company in which Consultant has any right, title, or interest and that is not being assigned to the Company hereby. 

(d) Original Development. Consultant represents and warrants to the Company that all work that Consultant performs for or has performed
for the Company, and all Work Product related to the Field that Consultant produces or has produced, will not knowingly infringe upon or violate and has not knowingly infringed upon or violated any patent, copyright, trade secret, or other property
right of any of Consultant’s former employers or of any other third party. Consultant has not and will not disclose to the Company, and has not and will not use in any of Consultant’s Work Product related to the Field, any confidential or
proprietary information belonging to others, unless both the owner thereof and the Company have consented. 

  
 4 

 (e) Definitions. For purposes of this Agreement, (i) the term “Work
Product” means all intellectual property, patents, trademarks, copyrights and trade secrets, and any applications therefor, literary works, software, documentation, memoranda, photographs, artwork, sound recordings, audiovisual works, ideas,
designs, inventions, discoveries, improvements, processes, algorithms, and so forth; and (ii) the term “Field” means (A) the treatment or therapy of gastroesophageal reflux or gastroesophageal reflux diseases and all esophageal
and extraesophageal conditions caused by gastroesophageal reflux or gastroesophageal reflux disease and/or obesity using electrostimulation in the stomach alone or in combination with the esophagus, (B) the treatment or therapy of any condition
or indication using electrostimulation in the esophagus, and (C) any other medical device or treatment method to which the Parties mutually agree in writing to include within the scope of Consultant’s obligations and Work Product, as may
be embodied in exclusive license agreements or assignment agreements of intellectual property that may occur, from time-to-time, pursuant to the Patent Assignment Agreement dated September 2, 2009, as may be amended from time to time, between
the Company, Consultant, and certain other parties. 
 (f) Acknowledgements. Consultant further acknowledges and agrees that the
damages resulting from any breach of the foregoing covenants may be intangible in whole or in part and that the Company is entitled to seek specific enforcement, injunctive relief and other equitable remedies in addition to monetary damages and
legal remedies, and Consultant hereby stipulates to the entering of such injunctive relief enforcing the provisions of this Section 6. Consultant hereby waives any bond or similar requirements for granting such injunctive relief. 

7. Non-Competition Agreement. Consultant agrees that, during the “Restricted Period” (as defined below), Consultant will not,
as an individual or as a partner, employee, agent, advisor, consultant or in any other capacity of or to any person, firm, corporation or other entity, directly or indirectly: 

(a) carry on any business or become involved in any business activity anywhere in the world as it relates to the Field (the
“Business”) or the Confidential Information; provided, however, that the foregoing shall not prohibit Consultant from owning 5% or less of the outstanding equity securities of a publicly traded entity; or 

(b) hire, or assist anyone else to hire, any employee or consultant of the Company who is at that time employed or engaged by the Company, or
was employed or engaged by the Company at any time during the six (6) months prior to the termination of Consultant’s engagement with the Company, or seek to persuade, or assist anyone else to seek to persuade, any such employee or
consultant of the Company to discontinue their employment or engagement with the Company; or 
 (c) induce or attempt to induce, or assist
anyone else to induce or attempt to induce, any customer of the Company to reduce or discontinue its business with the Company, or disclose to anyone else the name and/or requirements of any such customer. 

  
 5 

 For purposes of this Section 7, the term “Restricted Period” shall mean
(i) the Consulting Period plus (ii) a period of three (3) years following termination of this Agreement if terminated voluntarily by Consultant or by the Company for Cause. If the Company terminates this Agreement without Cause, then
the Restricted Period shall end on the date of such termination. For purposes of this Section 7, the Company shall have the right to terminate this Agreement for “Cause” only in the case of the following circumstances: 

(i) Consultant refuses to perform his duties pursuant to this Agreement (unless such duties shall be unlawful) or Consultant fails or is
unable (other than as a consequence of any illness, accident or other disability, as confirmed by a board-certified specialist authorized to practice medicine in the jurisdiction in which Consultant is examined for such purpose) to perform his
duties pursuant to this Agreement for a period in excess of 60 days in a manner reasonably satisfactory to the Board, provided (A) the Board has given Consultant written notice of his deficient performance, with such notice containing
reasonable specificity with respect to the deficiencies that need to be corrected or addressed in order to meet the Board’s expectations as to satisfactory performance of Consultant’s duties, (B) the deficiencies relate to matters
over which Consultant has sufficient responsibility and authority to enable Consultant to meet or exceed the expected level of performance in a reasonable amount of time, (C) the Board’s expectations with respect to the scope of
Consultant’s performance and the time in which Consultant is to render such performance are made in good faith and are reasonable under the circumstances, (D) the Board provides Consultant a period of at least 30 days in which to correct
or address such deficiencies, and (E) the Board’s ultimate decision with respect to such continued failure or inability to perform is not arbitrary or capricious and is not made in bad faith; 

(ii) Consultant’s embezzlement, misuse, or misappropriation of a material amount of Company funds or property; 

(iii) Consultant falsifies or otherwise alters any information, reports, documents or certificates made by Consultant in connection with his
services to the Company in a manner that Consultant knows or reasonably should have known to be false or misleading; 
 (iv) Consultant
engages in activities harmful to the reputation of the Company (other than as a consequence of good faith decisions made by Consultant in the normal performance of Consultant’s duties on behalf of the Company); or 

(v) Consultant violates Sections 5, 6, or 7 of this Agreement. 

Consultant agrees that the running of the time period set forth above with respect to any of subparagraphs (a) through (c) shall be
tolled with respect to any such subparagraph during any period of time during which Consultant violates the provisions of any such subparagraph. Nothing in this Section 7 shall prevent Consultant from performing Consultant’s duties
and responsibilities for the Company. 
 Consultant recognizes the broad territorial scope of the covenants above, but acknowledges and
agrees that the restrictions are reasonable and enforceable in view of, among other things, (1) the narrow range of activities prohibited, (2) the national and international markets in which the Company operates and plans to operate,
(3) the confidential, proprietary 

  
 6 

 
and trade secret information to which Consultant has or is likely to have access, (4) the fact that a business which competes with the Company in the Business could benefit greatly if it
were to obtain the Confidential Information of the Company, (5) the legitimate interests of the Company in protecting its Confidential Information, goodwill and relationships, (6) the limited duration of the restrictions set forth in this
Section 7, (7) the valuable confidential, proprietary and/or trade secret information which the Company possesses, and (8) Consultant’s past and anticipated future involvement in developing and maintaining the Confidential
Information of the Company and in developing, maintaining and fostering the Company’s customer relationships and the goodwill associated therewith and with the products and services of the Company. 

Consultant expressly agrees that the covenants set forth in this Section 7 are reasonable in light of the scope of the Business
conducted and to be conducted by the Company. The parties hereto agree that each such covenant shall be deemed to be a separate, distinct and divisible covenant if and to the extent necessary to permit the enforcement of any such covenant. If any
court or tribunal of competent jurisdiction shall refuse to enforce any of the foregoing covenants because the time limit applicable thereto is deemed unreasonable, it is expressly understood and agreed that any such covenant shall not be void, but
that for the purpose of such proceedings and in such jurisdiction, such time limitation shall be deemed reduced to the extent necessary to permit enforcement of any such covenant. If any court or tribunal of competent jurisdiction shall refuse to
enforce any of the foregoing covenants because they are more extensive (whether as to geographic area, scope of business or otherwise) than is deemed reasonable, it is expressly understood and agreed between the parties hereto that any such covenant
shall not be void, but that for the purpose of such proceedings and in such jurisdiction, the restrictions contained herein (whether as to geographic area, scope of business or otherwise) shall be deemed reduced to the extent necessary to permit
enforcement of any such covenant. 
 Consultant further acknowledges and agrees that the damages resulting from any breach of the foregoing
covenants may be intangible in whole or in part and that the Company is entitled to seek specific enforcement, injunctive relief and other equitable remedies in addition to monetary damages and legal remedies, and Consultant hereby stipulates to the
entering of such injunctive relief prohibiting Consultant from violating such covenants. 
 8. Compliance with Existing Agreements.
Consultant covenants that he will strictly observe, and comply fully with, all the provisions of his agreements with present and former employers, and to refrain from taking any action, or causing any action to be taken, that would directly or
indirectly violate any provision thereof. Consultant represents and warrants that he is not currently subject to any express or implied contractual obligations to any former employers under any proprietary rights, confidentiality, non-competition or
other arrangements or understandings that would adversely affect Consultant’s ability to provide services to the Company under this Agreement. If at any time Consultant has concerns that the duties or responsibilities assigned to him may
violate or have violated Consultant’s agreement with any present or future employer, Consultant shall promptly notify the Board in writing. 

9. Non-Waiver of Rights. The failure to enforce at any time any of the provisions of this Agreement or to require at any time
performance by the other party of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of either party thereafter to enforce
each and every provision in accordance with its terms. 

  
 7 

 10. Assignment. This Agreement shall be freely assignable by the Company and shall inure
to the benefit of, and be binding upon, the Company, its successors and assigns and/or any other corporate entity which shall succeed to the business presently being operated by the Company, but, being a contract for personal services, neither this
Agreement nor any rights hereunder are assignable by Consultant, except to the extent required under Section 6 of this Agreement in order for Consultant to convey such rights to the Company. 

11. Governing Law; Submission to Jurisdiction. This Agreement shall be interpreted in accordance with and governed by the laws of the
State of Missouri, without regard to the conflicts of law provisions thereof. The parties acknowledge that the Company is headquartered and has its principal place of business in Missouri, that the Company is likely to provide Confidential
Information emanating from Missouri, and that the Company has an interest in protecting such Confidential Information and other protectable interests under this Agreement pursuant to the laws of the State of Missouri. The parties hereto irrevocably
agree that any legal action or proceeding with respect to this Agreement shall only be brought in the federal or state courts in Missouri encompassing St. Louis County, Missouri, and each party hereby irrevocably submits with regard to such action
or proceeding to the exclusive jurisdiction of the aforesaid courts. 
 12. Amendments. No modification, amendment or waiver of any of
the provisions of this Agreement shall be effective unless in writing and signed by the parties hereto. 
 13. Notices. Any notices to
be given by either party hereunder shall be in writing and shall be deemed to have been duly given if delivered or mailed, certified or registered mail, postage prepaid, as follows: 

If to the Company: 
 EndoStim,
Inc. 
 4041 Forest Park Ave. 

Suite 127 
 St. Louis, Missouri
63108 
 Attention: Bevil J. Hogg, Chief Executive Officer 

with a copy (which shall not constitute notice) to: 

Bryan Cave LLP 
 One
Metropolitan Square 
 211 N. Broadway, Suite 3600 

St. Louis, Missouri 63102 

Attention: James L. Nouss, Jr. 

Facsimile: (314) 259-2020 

  
 8 

 If to Consultant: 

or to such other address as may have been furnished to the other party in writing. 

14. Relationship. Consultant is an independent contractor and is not an employee of the Company. Consultant is not covered by or
entitled to any benefits from the Company (including without limitation, health, dental, medical, disability, or life insurance; pension, retirement, profit sharing, savings, incentive, or bonus plans; vacation days or vacation or severance pay) by
virtue of this Agreement. 
 15. Entire Agreement. This Agreement, together with the Exhibits attached hereto, constitutes the entire
agreement between the parties and supersedes any and all prior consulting and similar agreements, written and/or oral between the Company and Consultant. Consultant agrees that the restrictive covenants contained in Sections 5, 6, and
7 of this Agreement, and any other agreement entered into by Consultant with the Company are separate covenants, independently enforceable, and that the expiration or enforceability of one such covenant shall have no effect on the duration or
enforceability of any similar covenant. 
 Remainder of page intentionally left blank; signature page follows 

  
 9 

 IN WITNESS WHEREOF, the Company and Consultant have executed the Agreement on the date first
above written. 
  

					
	COMPANY
		
		 	ENDOSTIM, INC.
			
		 	By:	 	/s/ Bevil J. Hogg
		 		 	Bevil J. Hogg
		 		 	Chief Executive Officer
	
	CONSULTANT
		
		 	/s/ Virender K. Sharma
		 	Virender K. Sharma, M.D.

 Signature page to Consulting and Non-Competition Agreement 

 EXHIBIT B 

Preexisting Work Product Not Assigned (pursuant to Section 6(c)), but only to the extent it is outside of the Field: 

The following patents, patent applications, any divisional, continuation, substitute, renewal or reissue of the applications and/or patents and any extensions
or continuations (in whole or in part) thereof: 
  

									
	 	  	 Patent/Patent

Application No
	  	 Title
	  	 Date Filed
	  	 Date Issued

	1.	  	U.S. Patent Application No. 12/030,222	  	Method and Apparatus for the Electrical Stimulation of the Pancreatico-Biliary System	  	February 13, 2008	  	Not Issued
	2.	  	PCT Application No. PCT/US08/53780	  	Method and Apparatus for the Electrical Stimulation of the Pancreatico-Biliary System	  	February 13, 2008	  	Not Issued
	3.	  	Provisional Patent Application No. 61/102,885	  	Method and Apparatus for Tissue Ablation	  	October 6, 2008	  	Not Issued

 AMENDMENT TO CONSULTING AND NON-COMPETITION AGREEMENT 

THIS AMENDMENT TO CONSULTING AND NON-COMPETITION AGREEMENT (this “Amendment”) is entered into this 1st day of July, 2010, by and between EndoStim, Inc., a Delaware corporation, and Virender K. Sharma (together, the “Parties”). All capitalized terms used herein and not otherwise
defined herein shall have the meanings ascribed to them in that certain Consulting and Non-Competition Agreement entered into on May 21, 2010, by and between the Parties (the “Consulting Agreement”). 

WHEREAS, Section 12 of the Consulting Agreement provides that the Consulting Agreement may only be changed by mutual written agreement of
the Parties; and 
 WHEREAS, the Parties desire to amend the Consulting Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual covenants of the Parties hereinafter expressed, it is hereby agreed as follows:

 1. Section 4. 

Section 4(b) of the Consulting Agreement is hereby deleted in its entirety and replaced with the following: 

(b) Cash Payments. Beginning September 1, 2010, contingent upon the close of a Series B round of approximately $6.0 million by the
Company the Company will pay Consultant a retainer of $50,000 per year, payable in accordance with the Company’s standard payroll practices, it being understood that such amount shall only be paid until this Agreement is terminated as provided
in Section 2. 
 Section 4 of the Consulting Agreement is herby amended to include a Section 4(d) written as following: 

(d) Options. Subject to approval by the Company’s Board of Directors (the “Board”) or a committee thereof, and contingent
upon the close of a Series B round of approximately $6.0 million by the Company Consultant will be granted options to purchase 50,000 shares (the “Grant”) of the Company’s common stock, $0.001 par value (the “Company
Stock”). The exercise price with respect to the options granted pursuant to the Grant will be equal to the fair market value of the Common Stock on the date of the Grant, as determined by the Board. The Grant will vest in 48 equal monthly
installments commencing on the Effective Date, and continuing to vest thereafter as long as the Consultant remains a consultant of the Company. Consultant’s options will expire, to the extent previously unexercised upon the earlier of ten years
from the date of grant or not less than six months after Consultant ceases to be a consultant of the Company. The options will in all respects be subject to the terms and provisions of any applicable stock bonus plan and stock option plan, and the
stock option agreement evidencing the grant of the options. Consultant stock options will be subject to accelerated vesting upon a merger or acquisition, as determined by the company’s Board of Directors in accordance with the Stock Option
Plan. 

 2. Miscellaneous. Except as amended by this Amendment, the Consulting Agreement
remains in full force and effect. This Amendment may be executed in one or more identical counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same instrument. This Agreement may be
executed and delivered by facsimile transmission or by exchange of emails containing PDF attachments and any such facsimile or PDF signatures hereon shall be deemed to be original signatures for all purposes. 

3. Headings. The section headings contained in this Amendment are inserted for convenience only and shall not affect in any way
the meaning or interpretation of this Amendment. 
 4. Governing Law. In order to establish with certainty that this Agreement
will be governed by one body of well-developed commercial law, the Company and Consultant hereto expressly agree that this Agreement shall be governed by, and construed in accordance with, the laws of the United States and the State of Missouri,
without regard to the conflicts of laws provisions thereof. In the event that either party commences a legal action pursuant to this Agreement, the parties hereto agree that the federal and state courts located in the State of Missouri shall have
exclusive jurisdiction over any such action. 
 •        INTENTIONAL END OF
PAGE; SIGNATURE PAGE FOLLOWS. 

  
 4 

 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the day and year first
above written. 
  

			
	ENDOSTIM, INC.
		
	By:	 	/s/ Bevil J. Hogg
		
	Name:	 	Bevil Hogg
		
	Title:	 	CEO
	
	/s/ Virender K. Sharma
	Virender K. SharmaEX-10.13

 EXPLANATORY NOTE: [*] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED AND
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
 Exhibit 10.13

 DEVELOPMENT AND SUPPLY AGREEMENT 

THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into this March 31, 2013 (the
“Execution Date”) between EndoStim, Inc., with its principal business address in St. Louis, MO, USA (“EndoStim”), and C.C.C. DEL URUGUAY S.A., a Uruguayan corporation with its principal
business address in Montevideo, Uruguay (“CCC”). 
 R E C I T A L S 

A. CCC is an ISO 13485 certified medical device company and has developed, in conjunction with EndoStim, and manufactures for EndoStim
an implantable pulse generator (the “LES Stimulator”), a programmer device and software (the “LES Programmer System”) and an implantable lead (the “LES Lead”) to apply an
electrical stimulation therapy for the treatment of Gastro-Esophageal Reflux Disease (GERD); and 
 B. EndoStim has conceived a second
generation implantable pulse generator (the “EndoStim IPG”); and 
 C. The EndoStim IPG is based on the pre-existing
technology of the LES Stimulator IPG (the “LES Stimulator IPG technology”); and 
 D. The EndoStim IPG will function
with pre-existing technology of the LES Programmer System (the “LES Programmer technology”); and 
 E. The EndoStim
IPG will function with pre-existing technology of the LES Lead (the “LES Lead technology”); and 
 F. EndoStim wishes
to engage the services of CCC to develop the EndoStim IPG and to deliver the EndoStim IPG documentation set; and 
 G. EndoStim wishes to
engage the services of CCC to manufacture the EndoStim IPG, the LES Programmer System, and the LES Lead, in order to be able to use it as defined herein; and 

H. The EndoStim IPG is considered a successor of the LES Stimulator as defined in the Licensing Agreement signed between the parties on
October 28, 2010; and 
 I. All licensing terms of the Licensing Agreement signed between the parties on October 28, 2010 applies
to the EndoStim IPG as defined herein. 

 A G R E E M E N T 

FOR AND IN CONSIDERATION of the foregoing Recitals, the mutual covenants expressed herein and other valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Definitions and Interpretation 

1.1 Definitions. In addition to terms defined herein, the following terms have the meanings assigned to them: 

 

	(a)	“Confidential Information” means all intellectual property, including software and other technical data, products and product designs, and information, materials and documents relating to
products, product designs, product testing, markets, business plans, including financial information, business opportunities and trade secrets, disclosed, orally or in any written form, by one party to another under the Agreement, but which is non-public, private or proprietary in nature. Confidential Information shall also include all summaries, analyses, documents, memoranda, notes and other writings, including all the terms, conditions and definitions
of this agreement and any and all exhibits attached hereto, prepared by either party containing or based on other Confidential Information; 

  

	(b)	“Deliverables” means the goods and services to be delivered or provided by CCC to EndoStim as provided in Section 2.2 and Exhibit A and/or otherwise described in this Agreement;

  

	(c)	“Pre-Existing Property” means all rights of a party to designs, inventions (whether patentable or not), copyrights, trademarks, trade secrets, processes, software, devices and other intellectual
property and confidential information owned or held by a party immediately prior to the execution of this Agreement; 

  

	(d)	“Resulting Property” means all test results, designs, inventions (whether patentable or not), copyrights, trademarks, trade secrets, processes, software, devices, confidential information and
other intellectual property developed by either party as a result of this Agreement; 

  

	(e)	“Field of Use” means the field of delivering electrical stimulation therapy to the Gastrointestinal (GI) tract for the treatment of Gastro-Esophageal Reflux Disease (GERD), or delivering
electrical stimulation therapy to the Esophagus and/or the Lower Esophageal Sphincter (LES) for the treatment of metabolic or Gastrointestinal conditions; 

  

	(f)	“Products” means the hardware and software associated with the EndoStim IPG, the LES Stimulator, LES Programmer System and the LES Lead to be delivered to EndoStim under this Agreement;

  

	(g)	“Unit” means the EndoStim IPG and the LES Lead, packaged together, to be delivered to EndoStim under this Agreement; 

 

	(h)	“Device” means any of the following: LES Stimulator, LES Lead, LES Programmer System, EndoStim IPG, and Units, as defined within this Agreement; 

 

	(i)	“Produced Device”, “Manufactured Device”, “Finished Device”, “Delivered Device” means a Device that has been produced at
CCC and: (i) has been shipped to a destination indicated by EndoStim; or (ii) has entered into CCC’s stock of finished products and is ready to ship; or (iii) has been held at any other production stage upon EndoStim request.

 1.2 Reference within Agreement. The words “herein”, “hereby”,
“hereunder”, “hereof, “hereto” and words of similar import refer to this Agreement as a whole and not to any particular section, paragraph or clause of this Agreement. References to sections, paragraphs or clauses refer to
the sections, paragraphs and clauses of this Agreement unless otherwise stated. 
 1.3 Currency. All sums of money expressed in
this Agreement are expressed in the lawful money of the United States of America. 
 2. Scope of the Agreement 

2.1 CCC shall, in accordance with the Schedule provided in Exhibit A, deliver the EndoStim IPG and the documentation set detailed in
Exhibit B, according to the specifications conceived by EndoStim detailed in Exhibit C (“EndoStim IPG Specifications”). CCC shall also manufacture and deliver the EndoStim IPGs, LES Stimulator, LES Programmer
Systems, and LES Leads ordered by EndoStim under the conditions established herein. 
 2.2 EndoStim IPG Deliverables. In
connection with CCC’s obligations described in Section 2.1, CCC shall deliver to EndoStim the deliverables identified in the Schedule in Exhibit A, at the conclusion of specified dates. 

2.3 Documentation Deliverables. CCC shall deliver to EndoStim the EndoStim IPG documentation set detailed in Exhibit B.

 2.4 Changes. EndoStim shall have the right to make reasonable changes to the EndoStim IPG Specifications whether before or
after the completion of the delivery of all the Deliverables under this Agreement. To the extent that any such changes materially increase or decrease CCC’s costs of performance or the time reasonably required for CCC’s performance, the
parties shall negotiate and agree upon an equitable adjustment in EndoStim’s payments hereunder or in the Schedule detailed in Exhibit A. 

2.5 Clinical Validation. Upon satisfactory receipt of the Deliverables and Deliverable Documents from CCC, EndoStim shall be
responsible for the clinical validation of the EndoStim IPG. 
 3. Testing 

3.1 CCC Testing. Each of the Products manufactured shall be tested by CCC before delivery to EndoStim in order to verify the
correct functioning. Testing shall be manufacturing testing in accordance with CCC standard manufacturing testing. 
 The verification testing of the
EndoStim IPG will be done according to the EN 45502-1 standard. EndoStim will be responsible for the tests that have to be performed at external laboratories. 

 3.2 Acceptance. CCC will provide evidence that the Products meet its
specifications. EndoStim shall accept the Products only upon successful demonstration of performance of the Products to their specifications. 

3.3 Warranty. CCC warrants that for the period of twenty four (24) months following the delivery of the LES Programmer
System to EndoStim, or implant of the LES Stimulator, LES Lead, or Units in a patient, the Products (i) will conform to the specifications; (ii) will be free from defects of workmanship and materials. EndoStim shall communicate to CCC the
implant dates of implantable products by serial number on a quarterly basis. 
 Upon non-compliance of any Product, CCC will, at its sole
expense, either (i) repair the applicable defective Product within reasonable time; (ii) replace the applicable defective Product within reasonable time; and/or (iii) and if none of the above is feasible within a reasonable time, CCC
will refund the amount for the non-compliant Products paid under this Agreement plus shipping and handling fees. Failures due to normal depletion of the battery and to incorrect use or handling of the Products are not covered by this warranty. If
EndoStim is in material breach with respect to the payment terms of this Agreement, as defined in Section 4, the warranty terms may be suspended by CCC until a satisfactory resolution is reached by both parties. 

3.4 Records. CCC will maintain accurate records for the production and testing of the Products and any related documents,
as required by applicable laws and regulations, and will make copies thereof available to EndoStim upon EndoStim’s request.  

3.5 Access and Inspections by EndoStim and Regulatory Agencies. CCC will: (i) allow EndoStim’s personnel to
observe the production of the Products and visit CCC’s facility at any time during the term of this Agreement, (ii) allow representatives of any regulatory agency at any time to inspect its facilities and to inspect the records of the
Products to verify compliance with its regulations and guidelines and other practices, and shall cooperate with the inspectors, (iii) disclose all documentation as requested by regulatory agencies, (iv) inform EndoStim if regulatory
agencies review any EndoStim specific documentation, and (v) will promptly notify EndoStim of the scheduling of any such inspection relating to the Products and agrees to allow EndoStim to send a representative to be present throughout the said
inspection. CCC will promptly send to EndoStim a copy of any reports, citations, or warning letters received by CCC in connection with an inspection by a regulatory agency to the extent such documents relate to or affect the Products. 

4. Cost of this Agreement. All the prices provided herein are for shipping FOB Montevideo.  

4.1 Development and Documentation Cost: [*], which shall be paid by EndoStim to CCC in accordance with the Schedule in Exhibit
A. All payments except the first one shall be performed by EndoStim within 15 days from receipt of a lawful invoice from CCC. The first payment shall be performed within 7 days after the signature of this agreement. CCC shall send EndoStim an
invoice for this payment immediately after the signature of this agreement. This price includes the delivery of all Deliverables detailed in Exhibit A. 
  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.] 

 4.2 Licensing Cost: There is no additional licensing cost. 

4.3 Price, ordering, and delivery of the Products: EndoStim shall place Orders (as defined below) for Devices and CCC shall
deliver such Devices at the unit prices set forth in the table below (all amounts are in US Dollars). 
 [*] 

LES Stimulator will continue to be supplied at a price as defined in the table above for the EndoStim IPG Alone and considering Section 4.6 below, as
applicable. As an example, if EndoStim were to order [*] Units and [*] LES Stimulators within the same Order, the pricing would be [*] per Unit and $[*] per LES Stimulator, plus component cost differential, per LES Stimulator. LES Lead, when ordered
to use with LES Stimulator, will continue to be supplied at a price as defined in the table above for the LES Lead Alone. 
 For the definition of the
Devices’ applicable prices in the tables above, the quantity will be calculated according to the following criteria for each Device: 
  

	 	•	 	Unit: the quantity of Units plus the quantity of EndoStim IPG alone included in the Order. 

  

	 	•	 	EndoStim IPG Alone: the quantity of Units plus the quantity of EndoStim IPG alone included in the Order. 

  

	 	•	 	LES Lead Alone: the quantity of Units plus the quantity of LES Lead alone included in the Order. 

  

	 	•	 	LES Programmer: the quantity of LES Programmer included in the Order. 

  

	 	•	 	LES Stimulator: the quantity of LES Stimulator included in the Order. 

 The pricing
shall be applicable for all Units delivered after the completion of the Milestone #3 of the Schedule detailed in Exhibit A. 

EndoStim shall provide one purchase order per semester for Units and LES Programmer Systems to be produced during a semester (the
“Order”). The pricing set forth above shall apply to the Order. 
 The Orders shall be provided a certain period in
advance to the delivery of the first batch of Devices (the “Minimum Lead Time”), depending on the absolute and the relative increase over the quantity of IPGs produced for EndoStim in the previous 6 (six) months. The Minimum
Lead Time of an Order shall be defined as detailed in the following table: 
  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.] 

 [*] 

The Devices included in the Order shall be produced distributed during the semester according to a schedule to be agreed between both parties
at the time the PO is accepted by CCC. The distribution could be uniformly or ramping up depending on the quantity of Devices included in the Order. 

The payment terms for the Devices will be: 

- [*] 
 - [*] 

Both parties agree to negotiate in good faith down payment terms for purchase orders of [*] Units or greater. 

All prices are expressed in US dollars and are FOB Montevideo. These prices correspond to Orders of at least 10 Units and are valid until
December 31, 2014, when they could be adjusted to reflect the impact of materials or labor costs. The parties agree to negotiate any such adjustment in good faith. All prices shall include all Uruguayan taxes (including but not limited to
income or withholding taxes and/or VAT, if applicable) and levies and other related payments. 
 4.4 Conditions for Pricing.
The prices provided in this Section 4 are based on the following conditions. If any of these conditions are changed, the prices will be reasonably changed by CCC upon prior written approval by EndoStim, to reflect CCC’s cost
changes. 
  

	(a)	The Units will be packaged in standard outer blister manufactured using a current CCC mold, with a new inner blister (for the combination of the EndoStim IPG and LES Lead in the same package) manufactured using a new
CCC mold. 

  

	(b)	Neither the packaging process nor any other production or testing processes will be validated. Sterilization validation will occur at the next CCC annual sterilization revalidation effort at CCC’s expense.

  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.] 

	(c)	The manufacturer tooling cost for the titanium can is not included in this quote. It is expected that this will cost approximately US[*]. This cost will be transferred directly to EndoStim without overhead or markup.

 4.5 Supply and Purchase Commitment. CCC shall commit to be able to produce a minimum quantity of a combination
of Units, EndoStim IPGs, and LES Leads per semester during the execution of this Agreement, upon reception of the corresponding Orders from EndoStim according to the terms defined in Section 4.3. These minimum quantities per semester shall be:

 [*] 
 EndoStim shall commit to place Orders
for a minimum quantity of a combination of Units, EndoStim IPGs, and LES Leads to be produced per semester during the execution of this Agreement, according to the terms defined in Section 4.3. These minimum quantities per semester shall be:

 [*] 
 Both parties agree to negotiate in
good faith and with commercially acceptable terms, a Supply Agreement for quantities greater than [*] Units per year to be purchased by EndoStim and delivered by CCC, within two years of execution of this Agreement. CCC agrees to support EndoStim
with production transfer activities if requested by EndoStim at any time. EndoStim shall pay CCC a reasonable price for providing any services requested by Endostim and described in the previous sentence, considering the price will include the work
to be performed and the necessary or useful manufacturing technology know-how to be transferred by CCC. 
  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential information.] 

 4.6 Mixed Orders and/or Future Units. Should CCC manufacture mixed orders and/or
future generation products for EndoStim, CCC agrees to provide volume discount on labor and common components that is reflective of total Units ordered by EndoStim, both present generation (LES Stimulator) and future generation (EndoStim IPG or
other future device). CCC also agrees that Orders already in process can change from one Unit version to the other, provided that EndoStim absorbs the cost of discarded components and products in process and the wasted labor, if any. 

CCC agrees to support future generation product development activities with mutually agreed upon product specifications and construction. Both parties agree
to negotiate in good faith and with commercially acceptable terms. 
 5. Term and Termination 

5.1 Term. This Agreement shall be in force from the Execution Date and shall continue in force until terminated by either party
at any time upon 90 days written notice. 
 5.2 Breach. If either party materially breaches this Agreement, and fails to remedy
that breach to the reasonable satisfaction of the non-breaching party within 30 days after receiving written notice of that breach from the non-breaching party, the non-breaching party may immediately terminate this Agreement by written notice to
the breaching party. 
 5.3 Force Majeure. The failure or delay of either party to perform fully any of its obligations under
this Agreement solely by reason of acts of God; acts of civil or military authority; civil disturbance; war; embargo; fire; a delay or default caused by common carriers; a regional shortage of facilities, fuel, energy or materials; laws,
regulations, acts or orders of any governmental agency or official of general application; or any other circumstance beyond its reasonable control which cannot reasonably be foreseen or provided against (“Force Majeure”) will be deemed not
to be a breach of this Agreement so long as the party so prevented from complying with this Agreement has not contributed to such Force Majeure, has used its best efforts to avoid such Force Majeure or to ameliorate its effects, and continues to
take all actions within its power to comply as fully as possible with the terms of this Agreement. In the event of any such Force Majeure, full performance of the obligations affected will be deferred until the Force Majeure ceases. This section
will not apply to excuse a failure to comply with the terms of this Agreement arising from any commercial dispute between a party and a third party or the failure by a party to secure any materials, supplies or other input for any reason not caused
by Force Majeure. 
 5.4 Internal Approval. This contract will be in full force and effect as of the date of signing unless,
within twenty-one (21) days of signing date, either party is unable to obtain board of directors approval of the Agreement and all its terms. If either company’s board of directors failed to ratify the contract during the twenty-one
(21) day period, the Agreement and all of its terms will be immediately terminated. 
 5.5 Consequences of Termination.
The termination of this Agreement by any party shall not relieve either party of its obligation to the other party with respect to payment and supply obligations accruing prior to the date of such expiration or termination. 

 Notwithstanding the above, if CCC breaches or voluntary terminates this Agreement for any reason
other than EndoStim non-payment or Breach of this Agreement, EndoStim shall have the right to require CCC to continue to fulfill some or all of any open Orders upon a termination occurring after the commencement of manufacturing activities. Such
completion of Orders shall continue to be subject to the terms and conditions of this Agreement. Furthermore, , in order to allow EndoStim to have sufficient time to identify and obtain similar replacement Products without interruption of
EndoStim’s demand, EndoStim shall be entitled to continue to place Orders as follows: (i) if by the termination date EndoStim has provided to CCC an Order and CCC has not finished any of the products corresponding to this Order yet,
EndoStim shall have the right to provide 3 (three) additional Orders for the production of Devices the 3 (three) semesters after the Order provided; or (ii) if by the termination date CCC is already delivering devices of the open Order(s),
EndoStim shall have the right to provide 4 (four) additional Orders for the production of Devices during the 4 (four) semesters following the completion of the open Order. Such Orders shall be limited, per Device, to Device volumes not to exceed
twice that of the number manufactured for EndoStim during the previous 6 (six) months. Orders of higher Device volumes or for accelerated delivery may be accepted at the discretion of CCC. Such Orders shall continue to be subject to the terms and
conditions of this Agreement even if such Devices are shipped after the effective date of termination of the Agreement. Notwithstanding the above, EndoStim is not under any obligation to continue to buy Products from CCC following CCC’s
voluntary termination of this Agreement. 
 If EndoStim materially breaches or voluntarily terminates this Agreement for any reason other
than CCC’s non-delivery of products or Breach of this Agreement, CCC shall have the right to cancel some or all of any open Orders upon a termination occurring after the commencement of manufacturing activities. If CCC decides to fulfill the
open Orders, EndoStim shall pay for the Devices according to the payment terms of this Agreement, even if such Devices are finished and/or shipped after the effective date of termination of the Agreement. If CCC decides to cancel the open Orders,
EndoStim shall pay for: (i) all the Devices that were produced; (ii) the cost of the components and materials incurred by CCC to produce the Devices of the open Order; and (iii) the pro-rata share for the work in progress of the units
in production, minus the down-payment executed for the open Order. 
 In the event of Device component obsolescence or lack of supply, both
parties agree to work together in good faith to find an alternative component(s). Incorporation of the component(s) in the Device(s) shall be handled under the design control process of CCC. CCC and EndoStim shall negotiate in good faith the cost to
incorporate the alternative component(s) in the Device(s). EndoStim shall pay CCC for the negotiated cost. 
 In the event of termination of
this Agreement by EndoStim before the completion of Milestone #3 of the Schedule detailed in the Exhibit A, CCC promptly shall deliver to EndoStim all of its work in progress under this Agreement, and EndoStim shall pay the applicable
pro-rata share for the work in progress. If the applicable pro-rata is lower than the payments performed by EndoStim, CCC shall not reimburse EndoStim the amount paid by EndoStim in excess of this pro-rata. If the termination occurs after the
completion of Milestone #3 of the Schedule detailed in the Exhibit A, EndoStim shall complete the payments detailed in the Exhibit A. 

 In the event of termination of this Agreement by CCC before the completion of Milestone #3 of the
Schedule detailed in the Exhibit A, CCC promptly shall deliver to EndoStim any payments received from EndoStim. EndoStim may reimburse CCC for any work completed and delivered, pro rata, if both parties agree. 

If either party defaults in the performance of any obligation under this Agreement then at all times after the default the other party will
have all of the rights and remedies provided by law and by this Agreement. However, under no circumstances, shall any Party violate any term or condition contained in Section 6 and/or Section 7. All rights and remedies of
either party granted or recognized in this Agreement are cumulative and may be exercised at any time and from time to time independently or in any combination and, for greater certainty, termination of this Agreement shall not preclude a party from
seeking such other remedies or enforcing such other rights as would otherwise be available. 
 5.6 Survival. Sections 3.3, 4.3,
4.5, 5.5 and 6 to 9, shall survive termination or expiration of this Agreement for any reason. 
 6. Confidentiality 

6.1 Non-disclosure. The parties acknowledge and agree that, from time to time, either of the parties may disclose Confidential
Information only to the other party for the purpose of better carrying out their obligations or to allow the receiving party to better carry out its obligations hereunder. The parties shall only use the Confidential Information for the purposes of
this Agreement and shall otherwise keep confidential and not disclose to any other person any of the Confidential Information except as expressly permitted by Section 6.3 hereof. 

6.2 Representatives. The parties may disclose Confidential Information to their respective directors, officers, employees,
authorized agents and professional advisers to the extent such persons have a need to know such information for the purpose of performing each party’s duties and obligations hereunder, provided that the party advises each such individual of the
terms of this Agreement and ensures that each such individual receives and hold such information as if that individual were a party to this Agreement. A party may, from time to time, designate in writing individuals as authorized representatives of
that party to whom Confidential Information may be provided directly by the disclosing party, and any Confidential Information so provided will be deemed to have been provided to the other party and be subject to this Agreement. Either party (the
“Disclosing Party”) may, from time to time, require the other party (the “Receiving Party”) to provide evidence to its reasonable satisfaction that all persons permitted by this paragraph to have
access to the Disclosing Party’s Confidential Information have executed Agreements, the terms of which are reasonably satisfactory to the Disclosing Party, are consistent with the terms of this Agreement and which may be enforced by the
Disclosing Party providing for the assignment of intellectual and other property rights to the Receiving Party or Disclosing Party, as appropriate and non-disclosure of Confidential Information. 

 6.3 Exceptions. The obligations of a party concerning the other party’s
Confidential Information shall not apply to information which: 
 (a) is or becomes widely known (defined as being published in
industry/medical journals or literature), other than by reason of a breach of this Agreement or, to the knowledge of the Receiving Party, a breach of a similar Agreement; 

(b) can be demonstrated in the Receiving Party’s records to have been independently developed by the Receiving Party without reference to
or based upon the other party’s Confidential Information; 
  

	 	(c)	the Disclosing Party agrees in writing need not be kept confidential; 

 (d) is required by law
or court of competent jurisdiction to be disclosed by the Receiving Party provided such party first gives prompt notice of the requirement to disclose to the Disclosing Party to allow that party to obtain an appropriate order or other protection
against the publication of such information. 
 6.4 Information’s Property. All Confidential Information provided
hereunder shall remain the property of the Disclosing Party. The Receiving Party shall, within ten days of a written request to do so or upon termination of the Agreement for any reason whatsoever, return to the Disclosing Party all Confidential
Information that has been provided in tangible form and shall, unless prohibited by law, destroy or otherwise render unintelligible all other Confidential Information. 

6.5 Injunctive Relief. The parties acknowledge that monetary damages would not be sufficient remedy for a breach of obligation of
confidentiality in this Agreement and agree that each party shall be entitled to seek and obtain appropriate equitable remedies, including injunctive relief, to prevent the unauthorized use or disclosure of any Confidential Information. 

6.6 Survival. The obligations under this Section 6 shall continue for a period of five years following the last day
on which CCC performs any services under this Agreement. 
 7. Intellectual Property Rights. 

7.1 Pre-Existing Property. The parties acknowledge and agree that all Pre-Existing Property is the property of the respective
party and that, except as expressly set out herein, nothing in this Agreement shall convey or otherwise grant any rights in or to any Pre-Existing Property from one party to the other. The parties expressly acknowledge and agree that the property of
the LES Stimulator IPG technology and documentation set, the LES Programmer System technology and documentation set, and the LES Lead technology and documentation set is regulated by the Licensing Agreement signed between the parties on
October 28, 2010. 

 7.2 EndoStim Rights to Deliverables. EndoStim will have the right to use and
reference the Pre-Existing Property of CCC incorporated in the EndoStim IPG, LES Stimulator, LES Programmer System, and LES Lead, in connection with a filing for any regulatory approvals. EndoStim will have the right to order to CCC to manufacture
the Products under the conditions established in this Agreement and in the previous Agreement signed between the two parties on October 28, 2010. EndoStim will have the right to file patent applications on Resulting Property, excluding any
Pre-Existing Property included therein. 
 7.3 CCC’s Representation. CCC is free to provide EndoStim with the services
under this Agreement, upon the terms contained in this Agreement and there are no contracts and/or restrictive covenants preventing full performance of CCC’s duties and obligations under this Agreement. To the best of CCC’s knowledge, any
and all work performed by CCC hereunder shall not infringe upon any copyright, patent, trademark, trade secret or other proprietary right of any third party including, without limitation, any former customer. 

7.4 EndoStim’s Representation. EndoStim is free to contract CCC to provide with the services under this Agreement, upon the
terms contained in this Agreement and there are no contracts and/or restrictive covenants preventing full performance of EndoStim’s duties and obligations under this Agreement. EndoStim declares that, to the best of its knowledge, any and all
requirements of the EndoStim IPG, which development is part of the object of this Agreement, do not infringe upon any copyright, patent, trademark, trade secret or other proprietary right of any third party, including, without limitation, any
company in which current employees of EndoStim were previously employed by. 
 7.5 Survival. The rights and obligations of the
parties under this section shall survive the termination of this Agreement and shall remain in full force and effect thereafter. 
 8. Dispute
Resolution 
 8.1 Initial Process. If any difference, controversy, claim or dispute arises out of or in connection with
this Agreement or in connection with any agreement to be entered into between the parties which is supplemental to or otherwise referred to in this Agreement (the “Dispute”), then the parties will seek to resolve the Dispute
amicably and in good faith. If the dispute is not resolved at this stage, it shall be conducted according Section 9.5. 
 8.2
No Waiver. No failure or delay on the part of any party in exercising any power or right under this Agreement will operate as a waiver of such power or right. No single or partial exercise of any right or power under this Agreement
will preclude any further or other exercise of such right or power. No modification or waiver of any provision of this Agreement and no consent to any departure by any party from any provision of this Agreement will be effective until the same is in
writing. Any such waiver or consent will be effective only in the specific instance and for the specific purpose for which it was given. No notice to or demand on any party in any circumstances will entitle such party to any other or further notice
or demand in similar or other circumstances. 

 9. Miscellaneous Provisions 

9.1 Notices. Any notice, direction, request or other communication required or contemplated by any provision of this Agreement
will be given in writing and will be given by (1) delivering by express courier or (2) faxing to the parties as follows: 
  

			
	If to EndoStim:	  	EndoStim, Inc.
		  	4041 Forest Park Ave, Suite 220
		  	St Louis, MO 63108
		  	Attention: Peggy Stohr
		  	Phone: +1 314 615 6345
		  	Fax: +1 314 615 6344
		
	If to CCC:	  	CCC del Uruguay
		  	Gral. Paz 1369
		  	11400, Montevideo, Uruguay
		  	Attention: Oscar de Oliveira Madeira
		  	Phone: +598 2600 7629 ext. 154
		  	Fax: +598 2601 6286

 Any party may change its fax number or address for service from time to time by written notice in accordance with this section.

 9.2 Assignment. This Agreement may not be assigned or subcontracted by CCC in whole or in part without the prior written
consent of EndoStim. 
 9.3 No Partnership. The parties acknowledge and agree that this Agreement does not create a partnership
or joint venture relationship between them. The performance by the parties of all duties and obligations under this Agreement shall be as independent contractors and not as agents or trustees of the other parties. Neither party shall owe any
fiduciary obligations to the other party, have any authority or capacity whatsoever to contract for or on behalf of or bind the other, and none of the employees of either of the parties shall be considered to be servants, employees or agents of the
other. 
 9.4 Acknowledgements, Cooperation and Confirmation. Upon the reasonable request of a party to this Agreement, the
other agrees to acknowledge to third parties the rights of the requesting party in the Pre-Existing Property. 
 9.5 Governing Law,
Venue and Jurisdiction. This Agreement will be governed by and interpreted in accordance with the laws of internal laws of the State of New York, USA without regard for its provisions for conflicts of law and the competent courts in New
York, New York shall have exclusive jurisdiction of any dispute with respect to the Agreement. 
 9.6 Counterparts and
Facsimile. 
 (a) This Agreement and any amendment, supplement, restatement or termination of any provision of this Agreement may be
executed and delivered in any number of counterparts, each of which when executed and delivered is an original but all of which taken together constitute one and the same instrument. 

 (b) This Agreement may be executed by facsimile and the facsimile execution pages will be binding
upon the executing party to the same extent as the original executed pages. The executing party covenants to provide originals of the facsimile execution pages for insertion into the original Agreement in place of the facsimile pages. 

9.7 Good Faith. EndoStim and CCC shall have a duty to act in good faith in the performance and enforcement of this Agreement.

 9.8 CCC’s Viability. CCC warrants that it has the financial capacity to perform and continue to perform its obligations
under this Agreement, that no legal proceedings have been threatened or brought against CCC that could threaten performance of this Agreement and that entering into this Agreement is not prohibited by any contract, applicable law, governmental
regulation or order by any court of competent jurisdiction. 
 9.9 EndoStim’s Viability. EndoStim warrants that it has the
financial capacity to perform and continue to perform its obligations under this Agreement, that no legal proceedings have been threatened or brought against EndoStim that could threaten performance of this Agreement and that entering into this
Agreement is not prohibited by any contract, applicable law, governmental regulation or order by any court of competent jurisdiction. 
 9.10
Continuity. In the event, CCC is unable to perform under the provisions of this agreement due to financial capacity such as bankruptcy, judgments, insolvency or other financial restrictions, CCC agrees, without obligation or charge to
EndoStim, to provide EndoStim with technical information or any other rights required so that EndoStim may obtain such parts or product from another source. Such technical information will include, without limitation, (a) manufacturing drawings
and specifications or raw materials and components comprising such parts, (b) any special tooling designs, along with a detailed description of the operation thereof, (c) a detailed list of all commercially available parts and components
purchased by CCC on the open market in connection with the Products. 
 9.11 Changes in Business. In the event of: (i) a
corporate divestiture by CCC, including the sale or disposition of a subsidiary, division or other significant business unit, (ii) the outsourcing of a business function, or (iii) a change of control of CCC (or its parent), including a
merger, corporate reorganization, or sale or exchange of all or substantially all of its (or its parents’) assets or stock (“Change of Control”), (i) CCC will communicate this event to EndoStim; and (ii) the successor to CCC
will have the obligation to continue to produce and ship Products/Services including, but not limited to manufacturing supply, product development, etc, under this Agreement including, the extension of Products/Services under this Agreement to
EndoStim. 

 9.12 Regulatory Support. CCC warrants that during the term of this Agreement they
will maintain the ISO 13485 certification and execute all development and production activities in adherence to known applicable U.S. FDA regulation and guidances, according to the terms of this Agreement and the Quality Agreement signed between
both parties. CCC will also support any U.S. FDA inspection activities, or inspections from other regulatory agencies, should they occur. CCC agrees to assist EndoStim with Mercosur activities supporting EndoStim product commercialization in
Mercosur markets, to include interaction with the Uruguayan government. EndoStim shall reimburse CCC’s reasonable cost of providing any services requested by EndoStim and described in the previous sentence. 

9.13 Construction. This Agreement constitutes the entire agreement of the parties, and there are no other oral or written
understandings, agreements or representations between EndoStim and CCC relating to the subject matter addressed in this Agreement. Any reference in this Agreement to any Article or Section refers to the corresponding Article or Section of this
Agreement. Any reference in this Agreement to any Exhibit refers to the corresponding Exhibit attached to this Agreement and all such Exhibits are incorporated herein by reference. The word “including” in this Agreement means
“including without limitation.” This Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision in this
Agreement. 
 (Signatures follow on next page) 

 IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written. 

 

			
	ENDOSTIM, INC.
		
	By:	 	 / S / B. Hogg

	Name:	 	B. Hogg
	Title:	 	CEO
		
	Date:	 	3/27/13
	
	C.C.C. DEL URUGUAY S.A.
		
	By:	 	 / S / Julio Arzuaga

	Name:	 	Julio Arzuaga
	Title:	 	General Manager
		
	Date:	 	3/27/13

 Exhibit A 

[*] 
  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.] 

 Exhibit B 

The following documents will be prepared by CCC and delivered to EndoStim: 

EndoStim System Requirements Document (updated as needed) 

EndoStim System Risk Control Mechanisms1 (updated as needed) 

EndoStim IPG Design Development and Verification Plan 
 EndoStim
IPG Specification 
 EndoStim IPG Requirements 
 EndoStim IPG
Rationale for use of LES Stimulator Firmware (can be included in Requirements document) 
 EndoStim IPG Mechanical Design Drawings 

EndoStim IPG Electrical Design Drawings (schematics, PCB layout, etc) 

EndoStim IPG Requirements Test Protocol 
 EndoStim IPG
Requirements Test Results 
 EndoStim IPG Manufacturing and Control Procedures 

EndoStim IPG Verification Report 
 EndoStim IPG Bill of Materials

 EndoStim IPG Product Configuration 
 EndoStim IPG Label
Documents (per EndoStim label design input) 
 EndoStim IPG Certificate of Materials and Manufacture
Processes2 
 EndoStim IPG Certificate of Sterilization Validation3 
 EndoStim IPG Certificate of Packaging Validation4

 EndoStim IPG Packaging and Shipping Validation5 

EndoStim IPG Conformance to EN45502-1:19976 

 

	1 	This document will include the input from CCC for the Risk Analysis documents to be prepared by Endostim. 

	2 	CCC will deliver a Certificate of Materials and Manufacture Processes for the Endostim IPG, based on the applicability of Biocompatibility Tests performed to other similar devices. 

	3 	If applicable, CCC will deliver a Certificate of Sterilization Validation Equivalence for the Endostim IPG, based on the sterilization process validation that has been performed for other similar devices

	4 	CCC will deliver a Certificate of Packaging Validation for the Endostim IPG, based on the packaging validation performed for other similar devices that uses the same packaging. 

	5 	CCC will deliver a 2 Year Packaging and Shipping Validation for the Endostim IPG, based on testing EndoStim will contract with CCC and/or an external test lab (CCC and lab tests fees paid for by EndoStim). EndoStim will
also pay for the materials and devices used in the tests (performed at CCC or at the external lab). This effort will not be confined to the timelines for all documentation deliverables. 

	6 	EndoStim will contract with external lab the tests that cannot be performed at CCC (lab tests fees paid for by EndoStim), including, but not limited to, the particulate matter test 

 Exhibit C 

[*] 
  

	[*	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]